Free Trial

Acelyrin (SLRN) Stock Price, News & Analysis

-0.08 (-1.94%)
(As of 05/28/2024 ET)
Today's Range
50-Day Range
52-Week Range
1.22 million shs
Average Volume
1.12 million shs
Market Capitalization
$401.07 million
P/E Ratio
Dividend Yield
Price Target

Acelyrin MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.57 Rating Score
443.2% Upside
$22.00 Price Target
Short Interest
11.18% of Float Sold Short
Dividend Strength
News Sentiment
0.96mentions of Acelyrin in the last 14 days
Based on 11 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($3.87) to ($4.49) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.39 out of 5 stars

Medical Sector

680th out of 931 stocks

Pharmaceutical Preparations Industry

321st out of 433 stocks

SLRN stock logo

About Acelyrin Stock (NASDAQ:SLRN)

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

SLRN Stock Price History

SLRN Stock News Headlines

Acelyrin, Inc. (SLRN)
SLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024
Acelyrin Founder Steps Down as CEO
ACELYRIN, INC. Announces Leadership Transition
SLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023
SLRN Apr 2024 2.500 put
See More Headlines
Receive SLRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acelyrin and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
7 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$6.74 per share


Free Float
Market Cap
$401.07 million
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Ms. Melanie Gloria B.S.N. (Age 46)
    Chief Operating Officer
    Comp: $667.52k
  • Ms. Mina Kim (Age 50)
    CEO & Director
  • Mr. Gilbert M. Labrucherie J.D. (Age 52)
    CFO & Chief Business Officer
  • Mr. Tyler Marciniak
    Head of Investor Relations & Communications
  • Ms. Sanam Pangali J.D.
    Chief Legal Officer & Head of People
  • Dr. Paul M. Peloso M.D. (Age 66)
    M.Sc., Chief Medical Officer
  • Ms. Suzy Buckhalter CPA
    Senior Director of Finance & Accounting
  • Mr. Kenneth A. Lock (Age 50)
    Chief Commercial Officer
  • Dr. Shephard Mpofu M.D.
    Chief Medical Officer
  • Ms. Patricia A. Turney (Age 57)
    Chief Technical Operations Officer

SLRN Stock Analysis - Frequently Asked Questions

Should I buy or sell Acelyrin stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acelyrin in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SLRN shares.
View SLRN analyst ratings
or view top-rated stocks.

What is Acelyrin's stock price target for 2024?

7 equities research analysts have issued 12 month target prices for Acelyrin's stock. Their SLRN share price targets range from $8.00 to $68.00. On average, they predict the company's share price to reach $22.00 in the next year. This suggests a possible upside of 443.2% from the stock's current price.
View analysts price targets for SLRN
or view top-rated stocks among Wall Street analysts.

How have SLRN shares performed in 2024?

Acelyrin's stock was trading at $7.46 on January 1st, 2024. Since then, SLRN stock has decreased by 45.7% and is now trading at $4.05.
View the best growth stocks for 2024 here

Are investors shorting Acelyrin?

Acelyrin saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 7,020,000 shares, a decline of 17.7% from the April 30th total of 8,530,000 shares. Based on an average daily trading volume, of 1,160,000 shares, the short-interest ratio is currently 6.1 days. Approximately 11.2% of the company's stock are short sold.
View Acelyrin's Short Interest

When is Acelyrin's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024.
View our SLRN earnings forecast

How were Acelyrin's earnings last quarter?

Acelyrin, Inc. (NASDAQ:SLRN) issued its quarterly earnings results on Thursday, March, 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.00) by $0.25.

When did Acelyrin IPO?

Acelyrin (SLRN) raised $540 million in an initial public offering on Friday, May 5th 2023. The company issued 30,000,000 shares at $18.00 per share.

Who are Acelyrin's major shareholders?

Acelyrin's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (6.31%), Artal Group S.A. (2.43%), Ikarian Capital LLC (1.58%), StemPoint Capital LP (0.72%), Jacobs Levy Equity Management Inc. (0.59%) and Kennedy Capital Management LLC (0.49%). Insiders that own company stock include Beth C Seidenberg, Biopartners Fund Ii Westlake, Mardi Dier, Ronald Oyston and Shao-Lee Lin.
View institutional ownership trends

How do I buy shares of Acelyrin?

Shares of SLRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SLRN) was last updated on 5/28/2024 by Staff

From Our Partners